VILLA GUARDIA, Italy, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the “Company”) announced today that the European Commission (“EC”) has granted Orphan Drug Designation to Defibrotide for the prevention of Graft versus Host Disease (“GvHD”). The designation follows a positive opinion released by the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”), on October 10, 2013.
Help employers find you! Check out all the jobs and post your resume.
